NCT02285244View on ClinicalTrials.gov

Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 12, 2015

Primary Completion Date

March 12, 2015

Study Completion Date

March 12, 2015

Conditions
Prolymphocytic LeukemiaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRichter Syndrome
Interventions
DRUG

sotrastaurin acetate

Given PO

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

James Blachly

OTHER

NCT02285244 - Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | Biotech Hunter | Biotech Hunter